Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 11 de 11
Filter
Add more filters










Publication year range
1.
J Diabetes Investig ; 13(10): 1788-1792, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35587395

ABSTRACT

Diabetic ketoacidosis (DKA) is one of the most serious acute metabolic complications of diabetes mellitus, and is characterized by hyperglycemia, metabolic acidosis and increased total ketone body concentrations. The main mechanism of DKA is a lack of insulin in the body. It has been reported that some immunological response is associated with insulin therapy. Herein, we report a case of serious DKA, which was induced by insulin allergy and anti-insulin antibody. This case clearly shows that DKA can be induced by insulin allergy and anti-insulin antibodies in individuals with type 2 diabetes treated with insulin. Furthermore, we should know that as the required insulin dose might be very high under severe insulin resistance and serious DKA in such cases, we should increase the insulin dose appropriately while monitoring pH, base excess and other factors.


Subject(s)
Diabetes Mellitus, Type 2 , Diabetic Ketoacidosis , Hypersensitivity , Diabetes Mellitus, Type 2/complications , Diabetes Mellitus, Type 2/drug therapy , Diabetic Ketoacidosis/complications , Diabetic Ketoacidosis/drug therapy , Humans , Hypersensitivity/complications , Hypersensitivity/drug therapy , Insulin/therapeutic use , Insulin Antibodies/adverse effects , Ketones
2.
J Med Case Rep ; 13(1): 79, 2019 Mar 11.
Article in English | MEDLINE | ID: mdl-30853027

ABSTRACT

BACKGROUND: Insulin autoimmune syndrome is a rare cause of hyperinsulinemic hypoglycemia characterized by autoantibodies to human insulin without previous insulin use. We report a case of a patient with hyperinsulinemic hypoglycemia possibly caused by insulin antibodies induced by insulin analogs and a novel therapeutic measure for this condition. CASE PRESENTATION: An 84-year-old Japanese man with a 28-year history of type 2 diabetes and chronic kidney disease, treated with biphasic insulin aspart 30, experienced persistent early morning hypoglycemia with daytime hyperglycemia. Despite discontinuation of biphasic insulin aspart 30, the condition persisted even after the patient ate small, frequent meals. Sodium bicarbonate was administered to correct the chronic metabolic acidosis, which then rectified the early morning glucose level. CONCLUSIONS: We believe this to be the first published case of a therapeutic approach to the treatment of hyperinsulinemic hypoglycemia associated with insulin antibodies that factors in blood pH and the correction of acidosis using sodium bicarbonate, which physicians could consider.


Subject(s)
Acidosis/drug therapy , Alkalies/therapeutic use , Autoimmune Diseases/drug therapy , Hyperinsulinism/drug therapy , Hypoglycemia/drug therapy , Insulin Antibodies/adverse effects , Sodium Bicarbonate/therapeutic use , Acidosis/etiology , Aged, 80 and over , Autoimmune Diseases/physiopathology , Humans , Hyperinsulinism/physiopathology , Hypoglycemia/physiopathology , Male , Syndrome
4.
Ann Biol Clin (Paris) ; 74(4): 490-4, 2016 Aug 01.
Article in English | MEDLINE | ID: mdl-27492703

ABSTRACT

Insulin-antibodies are a cause of misleading results in insulin immunoassays. They may also mediate deleterious blood glucose variations. A patient presented with overtiredness, recurrent episodes of sweating, dizziness and fainting fits. A fasting serum insulin assay performed on a Modular platform (Modular analytic E170, Roche Diagnostic, Meylan, France) showed a highly elevated value of 194.7 mIU/L, whereas on the same sample glucose and C-peptide levels were normal. Other immunometric insulin assays were performed, as well as antibodies anti-insulin radiobinding assay (RBA) and gel filtration chromatography (GFC). While complementary insulin assays yielded closer to normal fasting levels, the free insulin concentration assessed after PEG precipitation was 14.0 mIU/L and the RBA was positive. GFC revealed that most of the insulin was complexed with a 150 kDa molecule, corresponding to an immunoglobulin G (IgG). A high fasting serum insulin level in a patient with neuroglucopenic symptoms was related to a high insulin-antibody level, suggesting an insulin autoimmune syndrome.


Subject(s)
Autoimmune Diseases/blood , Insulin Antibodies/adverse effects , Insulin/analysis , Insulin/blood , Chromatography, Gel , Diabetes Mellitus/blood , Diabetes Mellitus/diagnosis , False Negative Reactions , Fasting/blood , Female , France , Humans , Immunoassay/methods , Immunoassay/standards , Insulin/immunology , Insulin Antibodies/blood , Middle Aged , Syndrome
6.
J Clin Endocrinol Metab ; 97(12): 4317-23, 2012 Dec.
Article in English | MEDLINE | ID: mdl-23074233

ABSTRACT

CONTEXT: We report a novel case of insulin autoimmune syndrome (IAS) presenting with hypoglycemia due to production of a monoclonal anti-insulin antibody in a patient subsequently found to have multiple myeloma (MM). OBJECTIVE: The aim of the study was to describe the 5-yr clinical course of a patient with IAS and MM and to characterize the origin and function of the pathogenic antibody. METHODS: We conducted a longitudinal case history with laboratory investigations to characterize the anti-insulin antibody subtype, specificity, affinity, and origin. RESULTS: The patient presented with IAS, which worsened during treatment of hepatitis C. The patient was then discovered to have a monoclonal gammopathy that progressed to MM. Treatment of the MM induced remission of the neoplasia and IAS, which then followed a synchronized course of progression and response to therapy. An anti-insulin IgG(3)-λ that bound specifically but with low affinity to the insulin B chain (amino acids 9-30) and that was distinct from the primary MM IgG(3)-κ clone was recovered from the patient and cloned. The antibody bound insulin and showed mutations of normal affinity maturation. CONCLUSIONS: We describe a case of MM heralded by IAS, where full characterization of the pathogenic antibody revealed that the monoclonal anti-insulin antibody had originated from a self-reactive clone.


Subject(s)
Hypoglycemia/etiology , Insulin Antibodies/adverse effects , Multiple Myeloma/complications , Multiple Myeloma/diagnosis , Antibodies, Monoclonal/adverse effects , Antibodies, Monoclonal/blood , Diagnosis, Differential , Humans , Hypoglycemia/diagnosis , Hypoglycemia/immunology , Hypoglycemia/pathology , Insulin Antibodies/blood , Male , Middle Aged , Multiple Myeloma/blood , Multiple Myeloma/immunology , Recurrence , Remission, Spontaneous , Severity of Illness Index , Tumor Cells, Cultured
9.
Intern Med ; 45(21): 1225-9, 2006.
Article in English | MEDLINE | ID: mdl-17139123

ABSTRACT

Here, we report a case of acute liver dysfunction complicated with uncontrollable glycemia due to insulin antibody. The patient was admitted to our hospital due to diabetic ketoacidosis. He was administered insulin immediately, however, his fasting plasma glucose level remained unstable despite the insulin treatment. Blood biochemistry revealed severe liver dysfunction, although no markers including hepatitis virus or autoantibodies associated with autoimmune liver diseases were detected. The 125I-insulin binding rate was high (54%). The characteristics of insulin antibody in this patient were similar to the antibodies of IAS patients, therefore we administered oral glucocorticoid against insulin antibody. The reduction in the 125I-insulin binding rate and the binding capacity of the high affinity site of insulin antibodies were balanced after oral glucocorticoid therapy. In addition, preprandial subcutaneous regular insulin was switched to lispro insulin. Postprandial plasma glucose levels were relatively improved by lispro insulin. The etiology of acute liver dysfunction was unknown, however, we believe that the combination of oral glucocorticoid and lispro insulin was suitable and useful for preventing recurrent liver dysfunction in this patient.


Subject(s)
Glucocorticoids/therapeutic use , Hypoglycemia/drug therapy , Insulin Antibodies/blood , Insulin/analogs & derivatives , Liver Diseases/drug therapy , Acute Disease , Adult , Diabetes Mellitus, Type 1/blood , Diabetes Mellitus, Type 1/complications , Diabetes Mellitus, Type 1/drug therapy , Humans , Hypoglycemia/blood , Hypoglycemia/complications , Insulin/therapeutic use , Insulin Antibodies/adverse effects , Insulin Lispro , Liver Diseases/blood , Liver Diseases/etiology , Male
10.
Eur J Clin Chem Clin Biochem ; 35(5): 365-7, 1997 May.
Article in English | MEDLINE | ID: mdl-9189740

ABSTRACT

Insulin was assayed directly using radioimmunoassay and immunometric assay in 31 sera containing anti-insulin antibodies. Anti-insulin antibodies were determined by radio-binding-assay. Insulin measurements were compared with those of free (unbound to antibodies, polyethylene glycol precipitated) insulin measurements. Compared with free insulin concentrations, radioimmunoassay and immunometric assay yielded falsely increased insulin results. The degree of overestimation by radioimmunoassay and by immunometric assay correlated with the anti-insulin antibody value. Anti-insulin antibodies still remain a possible pitfall in the insulin-specific immunometric assays which are now being widely used.


Subject(s)
Insulin Antibodies/adverse effects , Insulin Antibodies/blood , Insulin/immunology , False Positive Reactions , Humans , Immunoenzyme Techniques/adverse effects , Insulin/blood , Insulin/chemistry , Radioimmunoprecipitation Assay
SELECTION OF CITATIONS
SEARCH DETAIL
...